grant

The Development of selective and potent Kv1.3 ion channel blockers for the treatment of multiple sclerosis [ 2006 - 2009 ]

Also known as: Selective immunosuppressants for the treatment of multiple sclerosis

Research Grant

[Cite as https://purl.org/au-research/grants/nhmrc/406698]

Researchers: Dr Andrew Harvey (Principal investigator)

Brief description Building on the well-established path of developing drugs from Nature, the amplification of some unusual qualities of a naturally-occurring substance, khellinone, could lead to new treatments for autoimmune diseases such as multiple sclerosis and diabetes. Designed variants of khellinone are known to be very effective at preventing the destructive impact of the body's own T cells on the central nervous system that occurs in autoimmune disease.

Funding Amount $AUD 233,187.50

Funding Scheme Early Career Fellowships

Notes Industry ECF

Click to explore relationships graph
Identifiers
Viewed: [[ro.stat.viewed]]
ACN 633 798 857